Imeglimin for type 2 diabetes shows promise in small trial

SAN FRANCISCO – Imeglimin, the first in a new tetrahydrotriazine-containing class of oral glucose–lowering agents, markedly increased glucose-dependent insulin sensitivity and improved beta-cell…

…read more

Share